Factors such as long travel times to access care or limited parking options were reported as barriers to care.
Disparities in Multiple Myeloma
Advertisement
A drug used to treat some types of leukemia may offer patients with refractory multiple myeloma a new avenue for treatment.
Persistent or newly developed lymphopenia after diagnosis was also linked to an increased risk of mortality.
Individuals living in lower-income areas experience disproportionately higher rates of late-stage diagnoses and mortality.
responding physicians (92%) reported that prior authorization causes treatment delays for their patients
The proportion of myeloma cases linked to BMI and diabetes was higher in Black patients than White patients.
Patients who were Black or female were more likely to refuse treatment for multiple myeloma.
The study looked at disparities in outcomes of infusion with ide-cel or cilta-cel in patients with relapsed or refractory MM.
Significant delays in diagnosing multiple myeloma exist.
Expert Interviews
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.